ArticleInternational journal of clinical pharmacy2026
Effectiveness, safety, and pharmacoeconomic profile of Sophora flavescens film in the treatment of postpartum vaginal dysbiosis: a non-randomized controlled trial.
Article in International journal of clinical pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intravaginal Formulation Strategies for Vaginal Disorders: Optimizing Phytochemical and Biological Preparations-A Review.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
introductionSophora flavescens film (SFF), a topical traditional Chinese medicine that primarily contains matrine, has been approved in China since 2009 for chronic gynecological inflammation. However, evidence regarding its clinical value in the management of postpartum vaginal dysbiosis (PVD) remains limited.
aimThis study aimed to evaluate the effectiveness, safety, and pharmacoeconomic profile of SFF as an adjunct to conventional therapy in women with PVD.
methodThis single-center, open-label, non-randomized controlled trial was conducted among postpartum women (6-8 weeks after delivery) diagnosed with PVD. Participants were self-selected into either the SFF group (SFF plus conventional therapy) or the control group (conventional therapy alone). The primary outcome was the overall therapeutic effectiveness based on composite vaginal ecosystem indicators. Secondary outcomes included Vaginal Health Index Score (VHIS), Vaginal Inflammation Score (VIS), EQ-5D-5L health utility, EQ-VAS, and adverse events (AEs). Pharmacoeconomic evaluation was performed using a decision tree model to estimate the incremental cost-effectiveness ratio (ICER). Statistical analyses incorporated logistic regression and analysis of covariance (ANCOVA) with directed acyclic graph (DAG)-based confounder adjustments.
resultsIn total, 126 participants (63 per group) completed the study. The SFF group demonstrated a significantly higher overall effectiveness than the control group (adjusted odds ratio = 3.68, 95% confidence interval [CI]: 1.49-9.09, P = 0.005). Significant post-treatment improvements were observed in VHIS (mean difference [MD] = 2.420, 95% CI: 1.808-3.032, P < 0.001, η
conclusionWhen combined with conventional care, SFF significantly improved clinical, symptomatic, and quality-of-life outcomes in women with PVD, with favorable tolerability and short-term cost-effectiveness. These results support its potential clinical utility. However, confirmation through multicenter, double-blind, randomized controlled trials is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.